

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

CHANGE OF JOINT COMPANY SECRETARY

RESIGNATION OF JOINT COMPANY SECRETARY

The board of directors (the “**Board**”) of Shanghai Henlius Biotech, Inc. (the “**Company**”) announces that Mr. Guo Xinjun (“**Mr. Guo**”) has tendered his resignation from the positions as the secretary to the Board and a joint company secretary of the Company with effect from 5 November 2021. Mr. Guo will continue to act as a senior vice president of the Company. Mr. Guo has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

APPOINTMENT OF JOINT COMPANY SECRETARY

The Board is pleased to announce that it has approved the appointment of Ms. Wang Yan (“**Ms. Wang**”) as the secretary to the Board and a joint company secretary of the Company, with effect from 5 November 2021. The biographical details of Ms. Wang are set out as below:

Ms. Wang, aged 34, joined the Company in July 2013 and has successively acted as Science & Technology Administrative Commissioner, Supervisor of the Marketing Department, Securities Affairs Representative and Manager of Public Affairs Department, director of the Office of Board Secretary and executive director of Public Relationship of the Company. Ms. Wang obtained her Bachelor’s degree in Bio-pharmacy from Nanjing Forestry University in June 2010 and a Master’s degree in Biochemistry in July 2013 from the same university. Ms. Wang has been working closely with Mr. Guo in her role as the director of the Office of Board Secretary and has been in charge of the daily operation of the Office of Board Secretary.

Following the appointment of Ms. Wang as a joint company secretary of the Company, Ms. Leung Ching Ching (“**Ms. Leung**”), a current joint company secretary of the Company who possesses the requisite qualification and experience of a company secretary under Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”), will continue to act as the other joint company secretary of the Company and to assist Ms. Wang in discharging the duties of a company secretary of the Company under the Listing Rules.

In connection with the appointment of Ms. Wang as a joint company secretary of the Company, as Ms. Wang does not possess the specified qualifications strictly required under Rule 3.28, the Company has also applied to the Stock Exchange for, and the Stock Exchange has granted, a waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for a period of three years from the effective date of Ms. Wang's appointment, subject to the conditions that (i) Ms. Wang will be assisted by Ms. Leung throughout the waiver period; and (ii) the waiver can be revoked if there are material breaches of the Listing Rules by the Company. Accordingly, the Company will adopt the following arrangements:

- (a) Ms. Leung will work closely with Ms. Wang to jointly discharge the duties and responsibilities as the company secretaries of the Company and to assist Ms. Wang to acquire the relevant experience as required under the Listing Rules for a period of three years from the effective date of Ms. Wang's appointment;
- (b) the Company will ensure that Ms. Wang continues to have access to the relevant training and support in relation to the Listing Rules and the duties required of a company secretary of an issuer listed on the Stock Exchange and Ms. Wang will take no less than 15 hours of relevant professional training in each financial year; and
- (c) before the end of the three-year period, the qualifications and experience of Ms. Wang and the need for on-going assistance of Ms. Leung will be further evaluated by the Company. The Company will then endeavour to demonstrate to the Stock Exchange's satisfaction that Ms. Wang, having had the benefit of the assistance of Ms. Leung for the immediately preceding three years, has acquired the relevant experience such that a further waiver from Rules 3.28 and 8.17 will not be necessary.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Guo for his valuable contributions to the Company during his tenure as the secretary to the Board and a joint company secretary of the Company, as well as extend its warm welcome to Ms. Wang on her new appointments.

On Behalf of the Board
Shanghai Henlius Biotech, Inc.
Qiyu CHEN
Chairman

Hong Kong, 5 November 2021

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as the executive director, Mr. Qiyu Chen as the chairman and non-executive director, Mr. Yifang Wu, Ms. Xiaohui Guan, Dr. Aimin Hui and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.